Improving Submission Readiness for EMA and MHRA Regulatory Review
Customer Requirement
A pharmaceutical company required a comprehensive gap analysis of its clinical and non-clinical data to support upcoming regulatory submissions in both the European Union and the United Kingdom.
The client needed to understand whether their existing datasets met regulatory expectations and to identify any deficiencies that could impact submission acceptance, timelines, or approval outcomes.
Problem Statement
The client encountered multiple challenges while preparing their regulatory submissions, including:
- Differences between available data and regulatory expectations
- Missing, incomplete, or inconsistently documented information
- Uncertainty regarding jurisdiction-specific requirements
- Increased risk of regulatory queries, delays, or additional data requests
- Lack of a structured framework to assess and prioritize data gaps
These challenges created uncertainty around submission readiness and increased regulatory and timeline risks.
Key Objective
To evaluate the existing clinical and non-clinical data against EU and UK regulatory expectations, identify and categorize gaps, and support improved submission readiness and compliance.
Regulatory Support & Outcome
A structured review of the client’s clinical and non-clinical data was conducted to assess alignment with regulatory expectations. Available datasets were evaluated, and discrepancies were identified and categorized based on their potential regulatory impact: critical, major, or minor.
This structured assessment helped clarify areas requiring attention and enabled prioritization of actions needed to strengthen the submission package. The process improved overall submission readiness and reduced the likelihood of avoidable regulatory delays.
Business Impact
- Improved visibility into clinical and non-clinical data readiness
- Clear prioritization of gaps based on regulatory risk
- Reduced likelihood of regulatory queries and delays
- Strengthened alignment with EU and UK regulatory expectations
- Increased confidence in submission preparedness
Key Learning
Systematic evaluation of clinical and non-clinical data before submission helps identify potential regulatory risks early, allowing organizations to address deficiencies proactively and improve the likelihood of smooth regulatory review and approval.